Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P654: Monitoring of drug concentrations to predict remission under ustekinumab induction therapy in Crohn's disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Soufflet1, G. Boschetti1, X. Roblin3, C. Cuerq1,4, N. Williet3, R. Duclaux Loras5, P. Danion1, A. Mialon4, S. Paul6, B. Flourié1, S. Nancey*1

1Hospices Civils de Lyon, Gastroenterology, PIERRE BENITE, France, 3CHU Saint Etienne, Gastroenterology, Saint Etienne, France, 4Hospices Civils de Lyon, Biochemistry, Pierre Benite, France, 5Hospices Civils de Lyon, Gastroenterology Paediatry, Bron, France, 6CHU Saint Etienne, GIMAP, Saint Etienne, France

P655: Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Facchin*1, N. Vitulo2, B. Perini1, A. Buda3, F. Zingone4, C. Romualdi5, R. D'Incà4, E. Savarino4

1University of Padua, Department of Surgery, Oncology and Gastroenterology, Gastroenterology Section, Padova, Italy, 2University of Padua, Department of Biotechnology, Verona, Italy, 3S.Maria del Prato Hospital, Department of Oncological Gastrointestinal Surgery, Feltre( BL), Italy, 4University of Padua, Department of Oncological Gastrointestinal Surgery, Padova, Italy, 5University of Padua, Department of Biology, Padova, Italy

P656: Malnutrition rates are highest in pre-surgical Crohn’s disease when compared with active CD, CD in remission and UC in remission

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Sandall*1,2, K. Patel3, P. Shah2, D. O'Hanlon2, S. Smith1, A. Darakhshan4, P. Irving5, J. Sanderson5, M. Lomer1,2

1King's College London, Nutritional Sciences Division, London, UK, 2Guy's and St Thomas' NHS Foundation Trust, Nutrition and Dietetics, London, UK, 3St George’s Hospital NHS Foundation Trust, Gastroenterology, London, UK, 4Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, UK, 5Guy’s and St Thomas’ NHS Foundation Trust, Gastroenterology, London, UK

P657: Backwash ileitis not influences the risk of the pouchitis, but can increase the risk of the pouch dysplasia

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Banasiewicz*1, J. Paszkowski1

1University of Medical Sciences, General, Endocrynological Surgery and Gastrointestinal Oncology, Poznań, Poland

P658: Efficacy and safety of thalidomide in adults with refractory Crohn’s disease to maintain clinical remission: a retrospective cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Lin*1, Z. Huang1, K. Chao1, X. Gao1

1The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China

P659: Efficacy of switching from infliximab to golimumab in ulcerative colitis patients on deep remission

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Viazis*1, C. Pontas1, M. Gazouli2, T. Tsigaridas1, I. Tziortziotis1, C. Chatzievangelinou1, F. Gkeros1, M. Vraka1, A. Tsatsa1, E. Tsoukali1, M. Galanopoulos1, G. J. Mantzaris1

1Evangelismos Hospital, Gastroenterology Department, Athens, Greece, 2Medical School, National and Kapodistrian University of Athens, Department of Molecular Biology, Athens, Greece

P660: Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Flanagan*1, P. R. Gibson2, A. Ross1, O. Rosella3, S. J. Bell1

1St Vincent's Hospital, Gastroenterology, Melbourne, Australia, 2Alfred Health, Gastroenterology, Melbourne, Australia, 3Monash University Central Clinical School, Melbourne, Australia

P661: Early histological improvement demonstrated with oral ozanimod in patients with moderately to severely active Crohn’s disease in the STEPSTONE trial

ECCO '19 Copenhagen

Year: 2019
Authors:

B. G. Feagan*1, G. D'Haens2, K. Usiskin3, J. Liu3, D. Paul3, R. K. Pai4

1Robarts Clinical Trials, Western University, London, Canada, 2Academic Medical Center, Amsterdam, The Netherlands, 3Celgene Corporation, Summit, USA, 4Mayo Clinic, Scottsdale, USA

P662: Remission to vedolizumab is not higher in TNF-naïve compared with TNF-pre-treated patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Biedermann1, O. Mader2, P. Hruz3, P. Juillerat4, P. Michetti5, V. Pittet5, G. Rogler1, F. Seibold*2

1UniversitätsSpital Zürich, Zürich, Switzerland, 2Crohn Colitis Zentrum Bern, Bern, Switzerland, 3Universitätsspital Basel, Basel, Switzerland, 4Universitätsklinik Inselspital, Bern, Switzerland, 5Université de Lausanne, Lausanne, Switzerland

P663: The effect of vitamin D deficiency, and its correction, on healthcare utilisation among patients with inflammatory bowel disease (IBD)

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Chou1, J. Gubatan2, O. H. Nielsen3, A. Moss*1

1Beth Israel Deaconess Medical Center, Gastroenterology, Boston, USA, 2Stanford University Medical Center, Gastroenterology, Stanford, USA, 3University of Copenhagen, Clinical Medicine, Copenhagen, Denmark

P664: SB5 and reference adalimumab show cross-immunogenicity in patients with inflammatory bowel disease or rheumatoid arthritis

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Gonçalves*1, G. Myung2, E. Hong2, M. Park2, D. Jeong2, J. Ghil2

1Faculdade Farmacia Universidade Lisboa, iMed - Research Institute for Medicines, Lisboa, Portugal, 2Samsung Bioeips Co., Ltd., Incheon, South Korea

P665: 1-Year clinical and endoscopic follow-up of vedolizumab therapy in refractory PIBD patients

ECCO '19 Copenhagen

Year: 2019
Authors:

M. M. E. Jongsma*1, M. A. Aardoom1, L. de Ridder1, J. C. Escher1

1Erasmus Medical Center - Sophia Children's Hospital, Paediatric gastroenterology, Rotterdam, The Netherlands

P666: Safety of combination biologic and immunosuppressive therapy post-orthotopic liver transplantation in patients with inflammatory bowel disease: a systematic review

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Al Draiweesh*1,2, C. Ma1,3, M. Alkhattabi1,4, T. Nguyen5, M. Brahmania1, V. Jairath1,6

1Western University, Department of Medicine, Division of Gastroenterology, London, Ontario, Canada, 2King Fahad Specialist Hospital, Department of Medicine, Division of Gastroenterology, Dammam, Saudi Arabia, 3University of Calgary, Division of Gastroenterology and Hepatology, Calgary, Alberta, Canada, 4King Abdulaziz University, Department of Medicine, Rabigh, Saudi Arabia, 5Robarts Clinical Trials, Inc., London, Ontario, Canada, 6Western University, Department of Epidemiology and Biostatistics, London, Ontario, Canada

P667: Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates in 72 patients, a report from a district general hospital

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Radhakrishnan*1, H. Johnson1, K. Wade1, S. McLaughlin1

1Royal Bournemouth Hospital, Gastroenterology, Bournemouth, UK

P668: Ustekinumab induction effectiveness in Crohn’s disease in a real-life cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Rullan1, A. Elosua*1, C. Saldaña1, E. Amorena1, M. Vicuña1, S. Rubio1, Ó. Nantes1, C. Rodríguez1

1Complejo Hospitalario de Navarra, Gastroenterology and Hepatology, Pamplona, Spain

P669: Transmural healing is associated with higher infliximab trough levels in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Albshesh1, B. Unger1,2, S. Ben Horin2, R. Eliakim2, U. Kopylov2, D. Carter*2

1Chaim Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, 2Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel

P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Kunisaki*1, M. Tatsuno1, J. Kouyama1, C. Kawamoto1, H. Nishioka1, A. Mizoguchi1, Y. Nakamori1, T. Mitsui1, K. Chida1, Y. Hashimoto1, Y. Tamura1, A. Ikeda1, T. Ogashiwa1, R. Suzuki2, S. Maeda3, H. Kimura1

1Yokohama City University Medical Center, Inflammatory Bowel Disease Center, Yokohama, Japan, 2Kannai Suzuki Clinic, Yokohama, Japan, 3Yokohama City University Graduate School of Medicine, Department of Gastroenterology, Yokohama, Japan

P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study

ECCO '19 Copenhagen

Year: 2019
Authors:

J. R. White1,2,3, S. Din3, R. Ingram4, S. Foley4, M. A. Alam5, R. Robinson5, R. Francis2, E. Tucker2, M. Jalal6, D. Elphick6, E. Atallah1,7, A. Norman7, M. Amin8, A. Sajjad8, N. Heggs9, S. Meadowcroft9, G. Moran*1,2

1NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and The University of Nottingham, Nottingham, UK, 2Nottingham Digestive Diseases Centre, The University of Nottingham, Nottingham, UK, 3University Hospitals of Derby and Burton NHS Foundation Trust, Royal Derby Hospital, Derby, UK, 4Sherwood Forest Hospitals NHS Foundation Trust, Kings Mill Hospital, Nottingham, UK, 5University Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK, 6Chesterfield Royal Hospital NHS Foundation Trust, Chesterfield, UK, 7United Lincolnshire Hospitals NHS Trust, Lincoln County Hospital, Lincoln, UK, 8Kettering General Hospital NHS Foundation Trust, Kettering, UK, 9Takeda UK Ltd., High Wycombe, UK

P672: Drug therapy and monitoring for inflammatory bowel diseases: preliminary data from a multi-centre investigation in Asia

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Cai1, J. Shen1, J. Tong1, J. Lu1, Q. Zheng1, K. Wu2, J. Qian3, Z. Ran*1

1Division of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Shanghai Institute of Digestive Disease; Shanghai Inflammatory Bowel Disease Research Center, Shanghai, China, 2Department of Gastroenterology, Xijing Hospital, Air Force Military Medical University, Xi'an, China, 3Department of Gastroenterology, Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China

P673: Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics

ECCO '19 Copenhagen

Year: 2019
Authors:

H. Shiga*1, I. Abe1, M. Onodera1, R. Moroi1, M. Kuroha1, Y. Kanazawa1, Y. Kakuta1, Y. Kinouchi1,2, A. Masamune1

1Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan, 2Tohoku University, Health Administration Center, Center for the Advancement of Higher Education, Sendai, Japan